

# Risk Mitigation for off-label medicines in children

Mark Turner

BSc, MBChB(Hons), PhD, DRCOG, MRCP(UK), FRCPCH, FFPM(Hon)

Professor of Neonatology and Research Delivery, ULIV





DEPARTMENT
OF WOMEN'S
AND CHILDREN'S
HEALTH



# The argument

An integrated approach to risk mitigation is needed

- Goals based on specific intervention(s)
  - Maybe one goal at a time is best
- Team
- Implementation plan
- Evaluation












# Alder Hey Children's Hospital





# Paediatric Medicines Research Unit

# PAEDIATRIC MEDICINES RESEARCH UNIT

#### Aim:

To improve the health of babies, children and young people by research and development of better and safer medicines and their management.











# **Examples of Interventions**

- Guidelines about manipulations
  - MODRIC project
  - Needs a repository









## **Examples of Interventions**







These guidelines were developed as independent research commissioned by the National Institute for Health Research, Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0807-13260). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health

#### A Guide for Health Professionals









1.1 1.2 1.3 1.4	Clinical question Patients to whom the guideline is intended to apply Target users of the guideline Additional considerations	8 8 9
1.5	·	9
1.6		10
1.7	Recommendations	10
2. Dosage	forms	12
2.1	Tablets	12
	2.1.1 Systematic review evidence	12
	2.1.1.1 Bioavailability outcomes	12
	2.1.1.2 Weight and/or drug content outcomes	14
	2.1.1.3 Methods of manipulation outcomes	19
	2.1.1.4 Tablet shape	20
	2.1.1.5 Scored versus unscored tablet outcomes	20
	2.1.1.6 Additional outcomes	21
	2.1.2 Questionnaire	22
	2.1.3 Observational Study	23
	2.1.4 Evidence to recommendations – tablets	25
	2.1.5 Tablet recommendations	25
2.2	Capsules	26
2.2	2.2.1 Systematic Review evidence	26
	2.2.1 Oysternatic Neview evidence	20



1. Introduction





. Inti	roduct	ion			7	
	1.1	Clinica	l questi	ion	8	
	1.2				guideline is intended to apply 8	
	1.3				uideline 8	
	1.4	Additio		_		
	1.5	Guidel	2.2	Capsi	ules	26
	1.6	Guidel			Systematic Review evidence	26
	1.7	Recon			Questionnaire evidence	27
				2.2.3	Observational study	27
Do	sage fo	orme			Evidence to recommendations – capsules	28
. DO					Capsule recommendations	28
	2.1	Table	2.3	Sache		29
		2.1.1		2.3.1	Systematic review evidence	29
				2.3.2	Questionnaire	29
				2.3.3	Observational Study	29
				2.3.4	Evidence to recommendations – sachets	30
				2.3.5	Sachet recommendations	30
			2.4	Liquid	ls for oral administration	30
				2.4.1	Overall evidence	30
		2.1.2		2.4.2	Liquids for oral administration recommendations	31
		2.1.3	2.5	Nebu	liser solutions	31
		2.1.4		2.5.1	Systematic review evidence	31
		2.1.5		2.5.2	Questionnaire evidence	31
	2.2	Capsı			Observational study	31
		2.2.1		2.5.4	Evidence to recommendations – nebuliser solutions	32
				2.5.5	Nebuliser solution recommendations	32
			2.6	Intrav	enous injections	32
				2.6.1	Systematic review evidence	32
				2.6.2		32
				2.6.3	Observational study	33
				2.6.4	Evidence to recommendations – intravenous injections	33

**DEPARTMENT** 

OF WOMEN'S AND CHILDREN'S

**HEALTH** 







1. Introduct	tion		7	
1.1	Clinical quest	tion	8	
1.2	Patients to w	hom the guideline is intended to	apply 8	
1.3	Target users	of the guideline	8	
1.4	Additional co	nsiderations	9	
1.5	Guidel 2.2	Capsules	26	
1.6	Guidel	2.2.1 Systematic Review evide	ence 26	
1.7	Recon	2.2.2 Questionnaire evidence	27	
		2.2.3 Observational study	27	
2. Dosage f	orms	2.2.4 Evidence to recommend	•	
2.1	Table	2.2.5 Capsule recommendation		
2.1	2.1.1 2.3	Sachets	2.6.5 Intravenous injection recommendations	34
	2.1.1	2.3.1 Systematic review	Injections for subcutaneous administration	34
		2.3.2 Questionnaire	2.7.1 Overall evidence	34
		2.3.3 Observational Stu	2.7.2 Subcutaneous injection recommendations	35
		2.3.4 Evidence to recor	Transdermal patches	35
	2.4	2.3.5 Sachet recommer 2.8	·	35
	2.4	Liquids for oral adminis	<ul><li>2.8.1 Systematic review evidence</li><li>2.8.2 Questionnaire</li></ul>	35
	2.1.2	2.4.1 Overall evidence		33
	2.1.3 2.5	2.4.2 Liquids for oral ac Nebuliser solutions	<ul><li>2.8.3 Observational study</li><li>2.8.4 Evidence to recommendations – transdermal patches</li></ul>	36
	2.1.4	2.5.1 Systematic review		37
	2.1.5	2.5.1 Systematic review 2.5.2 Questionnaire evi 2.9	2.8.5 Transdermal patch recommendations	37
2.2	Capsı	2.5.3 Observational stu	Suppositories	37
2.2	2.2.1	2.5.4 Evidence to recor	2.9.1 Systematic review evidence 2.9.2 Questionnaire evidence	37 37
	2.2.1	2.5.5 Nebuliser solution		38
	2.6	Intravenous injections	2.9.3 Observational study	38
		2.6.1 Systematic reviev	2.9.4 Evidence to recommendations – suppositories	39
		2.6.2 Questionnaire evi 2.10	2.9.5 Suppository recommendations	
		2.6.3 Observational stu <sup>2.10</sup>	Enemas	39
		2.6.4 Evidence to recor	2.10.1 Systematic review evidence	39
			2.10.2 Questionnaire	40
			2.10.3 Observational study	40
			2.10.4 Evidence to recommendations – enemas	40
			2.10.5 Enema recommendations	40









Home » MedslQ » Patient Support » Creating a Pill School – The Kidzmed Project

**QI Central** 

#### Creating a Pill School – The Kidzmed Project

Creating a pill school to teach children and young people how to take tablet medication.

#### The Problem

Tablets are safer, more convenient and cheaper than liquid medications. Children and young people (CYP) often remain on liquids due to habit, reluctance to change or staff and parents' lack of knowledge about switching to tablets.

#### Aims

This initiative started off within one team in our children's hospital to train staff and embed a system of looking for and converting eligible children to tablet medication.



#### **Learning and Next Steps**

- Make learning fun. Learn in teams who normally work together
- Data collection is not difficult but does need close steerage. Once we had enough cost improvement data it opened doors to organisational leaders to help spread the project
- Patient and parents involvement at all stages is really helpful and helps drives the project as the improvement transformed their lives and they are keen to share their experiences

Teaching tablet swallowing is easy. This is not a new idea and we know of individual clinicians who have been teaching their patients how to swallow tablets for many years.

Read the full publication in Archives of Disease in Childhood: Tse Y, Vasey N, Dua D, et al. The KidzMed project: teaching children to swallow tablet medication. Archives of Disease in Childhood. Published Online First: 08 October 2019. doi: 10.1136/archdischild-2019-317512.

Project Lead: Yincent Tse, Consultant Paediatric Nephrologist; Nicola Vasey, Lead Paediatric Pharmacist; Ailsa Pickering, Senior Sister in Paediatric Infectious Disease; Emma Lim, Consultant Paediatrician.

Organisation: Great North Children's Hospital, Newcastle upon Tyne

https://qicentral.rcpch.ac.uk/medsiq/patient-support/creating-a-pill-school-the-kidzmed-project/

### **CAT Study**



Open access Original research

# BMJ Open Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT))

Louise Bracken , <sup>1</sup> Emma McDonough, <sup>1</sup> Samantha Ashleigh, <sup>2</sup> Fiona Wilson, <sup>2</sup> Joanne Shakeshaft, <sup>1</sup> Udeme Ohia, <sup>2</sup> Punam Mistry, <sup>3</sup> Huw Jones, <sup>4</sup> Nazim Kanji, <sup>4</sup> Fang Liu, <sup>5</sup> Matthew Peak <sup>1,2</sup>

To cite: Bracken L, McDonough E, Ashleigh S, et al. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable

#### ABSTRACT

Objective Feasibility study to investigate the acceptability of different-sized placebo tablets in children aged 4–12 years.

Design and setting Clinical Research Facilities, inpatient wards and outpatient clinics within a Regional Paediatric Hospital and/or District General Hospital. Healthy children

#### Strengths and limitations of this study

This study was conducted in both inpatients and healthy children to determine the overall acceptability (which includes swallowability, volume of water consumed and taste) of tablets in both children who

https://bmjopen.bmj.com/content/bmjopen/10/10/e036508.full.pdf





















#### STUDY PROTOCOL

#### **PADDINGTON**

Parent co-Designed Drug Information for parents and Guardians Taking Neonates home



## **Paddington**



#### Preparation:

- What do parents want / need?
- What can staff do?
- What are the gaps?

Development of resources with parents:

- Construction
- Evaluation









# The impact of paediatric dose range checking software

**Table 1** Summary of prescription overdosing error data and severity of reported overdosing-related clinical incidents

	Preintervention	Postintervention
Number of electronic prescriptions completed	131612	136803
Incidence of overdosing errors	12/847 (1.4%)	9/684 (1.3%)
Proportion of overdosing errors classified as minor errors	8/12 (66.7%)	7/9 (77.8%)
Proportion of overdosing errors classified as significant errors	4/12 (33.3%)	2/9 (22.2%)
Total overdosing-related clinical incidents	28	32
Proportion of overdosing incidents resulting in 'No Harm'	7/28 (25.0%)	17/32 (53.1%)
Proportion of overdosing incidents resulting in 'Near Misses'	20/28 (71.4%)	15/32 (46.9%)
Proportion of overdosing incidents resulting in 'Minor Harm'	1/28 (3.6%)	0/32 (0.0 %)

Neame M, et al. Eur J Hosp Pharm 2021;28:e18-e22. doi:10.1136/ejhpharm-2020-002244









# The impact of paediatric dose range checking software

```
Summary of prescription overdosing error data and severity
of rej
      ...use of this software does not
   reliably prevent overdosing errors...
Incide
   appropriate training and prescription
Propoi
    checking processes should always
Total c
   continue alongside these
'No Ha
   interventions"
Proportion of overdosing incidents resulting in
                        1/28 (3.6%)
                                  0/32 (0.0 %)
'Minor Harm'
```

Neame M, et al. Eur J Hosp Pharm 2021;28:e18-e22. doi:10.1136/ejhpharm-2020-002244











## **Examples of "Guidelines"**

#### 2022

- ENFit system
- Off Label Use of Chloral Hydrate to sedate neonates and children in critical care
- Administration of Rectal Diazepam to Neonates and Infants to Treat Seizures Prior to Hospital Admission

#### 2021

- Use of Steroid Medication Warning Cards for Children and Young People
- Off label use of Chloral Hydrate in the Management of Intrusive Movement and Motor Disorders in Children and Young People
- The use of chlorhexidine for skin cleansing in neonates

#### 2020

- Alternative parenteral acid suppressants covering main indications of IV rantidine in children
- Choosing an oral liquid medicine for children December 2020
- Domperidone and ECG monitoring interim statement January 2020

#### 2019

• The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice – update

#### 2018

• Using Standardised Strengths of Unlicensed Liquid Medicines in Children – updated May 2022

http://nppg.org.uk/position-statements/



DEPARTMENT
OF WOMEN'S
AND CHILDREN'S
HEALTH





## Has this research changed practice?

- Publication
- Journal Club
- Grand Round
- Newsletters
- Screensavers...









## Has this research changed practice?











#### What is needed?

Move from research and evaluation into changing clinical practice

- Quality Improvement
- Mandate from health care system
- Accountability to health care system
  - Regular review
  - Consequences of failure and success







# **Quality Improvement**

- an <u>organised</u>, multifaceted approach
  - includes teams from multiple healthcare sites
  - coming together to <u>learn, apply</u> and share improvement methods, ideas and <u>data</u>
- on <u>service performance</u> for a given healthcare topic.

Wells S, et al. BMJ Qual Saf 2018;27:226–240. doi:10.1136/bmjqs-2017-006926







# **Quality Improvement**

- Teams are supported by faculty of experts
- Between meetings:
  - Teams are provided with coaching
  - Tasked to apply quality improvement methods, (such as Plan-Do-Study-Act cycles)
- Teams learn faster and are more effective when <u>collaborating</u> and <u>benchmarking</u> with other teams

Wells S, et al. BMJ Qual Saf 2018;27:226–240. doi:10.1136/bmjqs-2017-006926







# **Quality Improvement**

- An improvement was reported in 83% of the studies (32/39) included in a systematic review
- Collaboratives reporting success generally:
  - addressed relatively straightforward aspects of care,
  - had a strong evidence base
  - noted a clear evidence-practice gap in an accepted clinical pathway or guideline.

Wells S, et al. BMJ Qual Saf 2018;27:226–240. doi:10.1136/bmjqs-2017-006926







# Mandate from Health Care System

- Provide resources
- Demonstrate importance
- What do we stop doing to make room for this?
- Hospital
  - Departments
- Region
  - Facilities
- Country
  - Regions
  - Comparable facilities









# Accountability

If you don't check it, it doesn't get done

- Who goes to jail if it doesn't happen?
- Who gets a prize if it does happen?

- Not the same as Responsibility
  - Who does the work?
- Accountability and Responsibility need to be described









#### Conclusion

An integrated approach to risk mitigation is needed

- Goals based on specific intervention(s)
  - Maybe one goal at a time is best
- Team
- Implementation plan
- Evaluation

Quality Improvement







